ArticleTranslational oncology2026
Shared inflammatory-metabolic transcriptional effects in tubulointerstitial fibrosis and clear cell renal cell carcinoma.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal tubulointerstitial fibrosis and clear cell renal cell carcinoma (ccRCC) are distinct diseases that both exhibit inflammatory and metabolic remodeling. We investigated whether independently analyzed human fibrosis and ccRCC transcriptomes show reproducible disease-associated transcriptional overlap.
methodsTCGA-KIRC (533 primary tumors and 72 solid-tissue normal samples) and GSE12682 (23 fibrosis and 13 healthy tubulointerstitial samples) were analyzed independently before gene-symbol alignment. Shared effects required FDR < 0.05, absolute log2 fold change ≥ 0.5, and concordant disease-associated direction. GSE328575 (65,770 cells) was used for descriptive single-cell localization. Species-resolved RT-qPCR assessed HADHA, ACSL4, PPARA, and PPARGC1A in TGF-β1-treated HK-2 and NRK-52E cells and in 786-O versus HK-2 cells.
resultsAmong 11,805 aligned genes, 6690 (56.7%) showed concordant directions and 64 met the full shared-effect criteria, including 51 shared-upregulated and 13 shared-downregulated genes. Genome-wide effects were modestly but significantly correlated (Spearman ρ=0.224, P = 1.05×10⁻¹³³). Both diseases showed increased inflammatory and reduced fatty-acid-oxidation programs; S100A9 was the only independently shared member of the curated candidate panel. RT-qPCR showed decreased HADHA, PPARA, and PPARGC1A and increased ACSL4 across both TGF-β1-treated tubular models and 786-O versus HK-2 cells.
conclusionsHuman bulk-tissue analyses identified a reproducible but limited inflammatory-metabolic overlap between fibrosis and ccRCC, with experimental mRNA-level validation of selected metabolic genes. The findings do not establish causality, direct HADHA-ACSL4 regulation, ferroptosis execution, or treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.